Related Experiment Videos
Current surfactant use in premature infants
1Neonatal Division, Department of Pediatrics, University of Vermont College of Medicine, Burlington, Vermont, USA. gautham.suresh@vtmednet.org
Insights
Exogenous surfactant therapy improves outcomes for preterm infants with respiratory distress syndrome (RDS). Prophylactic or early treatment with multiple doses of natural surfactant offers the best results with minimal adverse effects.
Area of Science:
- Neonatology
- Pulmonology
- Pediatric Critical Care
Background:
- Respiratory Distress Syndrome (RDS) is a common condition in preterm infants.
- Exogenous surfactant therapy has revolutionized RDS management.
- Both natural and synthetic surfactants are available, with natural surfactants showing advantages.
Purpose of the Study:
- To review the current evidence on exogenous surfactant therapy for RDS.
- To compare different surfactant administration strategies.
- To assess the safety and long-term outcomes of surfactant therapy.
Main Methods:
- Systematic review of clinical studies and trials.
- Meta-analysis of treatment outcomes, including mortality and morbidity.
- Evaluation of prophylactic versus rescue surfactant administration.
- Comparison of single versus multiple dosing strategies.
Main Results:
- Exogenous surfactant therapy significantly improves clinical outcomes and reduces mortality in preterm infants with RDS.
- Prophylactic surfactant administration is more beneficial than rescue therapy.
- Early treatment (before 2 hours) and multiple doses are superior to later treatment and single doses.
- Natural surfactants offer advantages over synthetic options.
- Adverse effects are infrequent and generally not serious.
Conclusions:
- Exogenous surfactant therapy is a cornerstone in managing preterm infants with RDS.
- Optimal use involves prophylactic or early administration of multiple doses, preferably natural surfactant.
- Long-term follow-up data are reassuring.
- Further research is needed to refine surfactant use with other respiratory interventions.
Abstract:
Exogenous surfactant therapy has been a significant advance in the management of preterm infants with RDS. It has become established as a standard part of the management of such infants. Both natural and synthetic surfactants lead to clinical improvement and decreased mortality, with natural surfactants having additional advantages over currently available synthetic surfactants. The use of prophylactic surfactant administered after initial stabilization at birth to infants at risk for RDS has benefits compared with rescue surfactant given to treat infants with established RDS. In infants who do not receive prophylaxis, earlier treatment (before 2 hours) has benefits over later treatment. The use of multiple doses of surfactant is a superior strategy to the use of a single dose, whereas the use of a higher threshold for retreatment seems to be as effective as a low threshold. Adverse effects of surfactant therapy are infrequent and usually not serious. Long-term follow-up of infants treated with surfactant in the neonatal period is reassuring. In the future we are likely to see the development of new types of surfactants. Further research is required to determine the optimal use of surfactant in conjunction with other respiratory interventions.